Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection
(IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early
treatment diabetic retinopathy study (ETDRS) chart in patients with diabetic macular edema
(DME) with central involvement.